Onlymyhealth1h
FDA Approves First-Ever Myasthenia Gravis Treatment For Children—A Game Changer In Pediatric Care
The FDA has approved Soliris the first-ever treatment for children with generalized myasthenia gravis gMG offering new hope in pediatric neuromuscular care Learn more!
Healio10h
FDA approves expanded label for Iluvien
The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis ...
Repurposed FDA-approved drug could help treat high-grade glioma
High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...
Medical Device Network on MSN19h
FDA approves early feasibility study of Valcare’s transcatheter device
The US Food and Drug Administration (FDA) has granted approval for Valcare Medical’s investigational device exemption application, allowing it to begin an early feasibility study of its transcatheter ...
Clinical Pain Advisor1d
FDA Drug Approval Decisions Expected in April 2025
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Multiple Sclerosis News Today1d
FDA approves prefilled syringe formulation of Ani’s Cortrophin Gel
The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...
Managed Healthcare Executive2d
FDA Approves First Generics of Xarelto
Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...
dvm3609h
FDA conditionally approves first drug for feline subclinical hypertrophic cardiomyopathy
Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...
Healio2d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...
Targeted Oncology11h
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.